Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research

C. Bakkers, G.A.A.M. Simkens, I.H.J.T. De Hingh*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

3 Citations (Web of Science)

Abstract

There is a lack of randomized or high-quality intention-to-treat cohort studies addressing the role of systemic therapy in addition to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as part of the treatment of colorectal peritoneal metastases (PM). Therefore, the choice whether or not to treat patients with systemic therapy is currently mainly based on expert opinion. As a result, treatment with neoadjuvant and/or adjuvant systemic therapy is implemented in various ways around the world. The aim of this review was to provide an overview of recent insights with regard to the systemic treatment of PM of colorectal origin obtained from clinical studies and translational research.
Original languageEnglish
Pages (from-to)S206-S213
Number of pages8
JournalJournal of Gastrointestinal Oncology
Volume12
DOIs
Publication statusPublished - 1 Apr 2021

Keywords

  • Systemic therapy
  • cytoreductive surgery (CRS)
  • hyperthermic intraperitoneal chemotherapy (HIPEC)
  • peritoneal metastases (PM)
  • colorectal cancer
  • CONSENSUS MOLECULAR SUBTYPES
  • RESECTABLE LIVER METASTASES
  • COLON-CANCER
  • 1ST-LINE TREATMENT
  • RAS MUTATIONS
  • POSTOPERATIVE COMPLICATIONS
  • CURATIVE TREATMENT
  • RANDOMIZED-TRIAL
  • BRAF MUTATION
  • STAGE-II

Cite this